Menu

NYU Halts Studies, Suspends Investigator

Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

Jun 28, 2016
Bob Grant

WIKIMEDIA, EVERYONE'S IDLENew York University (NYU) School of Medicine has shuttered eight studies on an investigational drug to treat psychological trauma, according to documents obtained by The New York Times. The US Food and Drug Administration (FDA) conducted an investigation of the trials last year. In a letter to the studies’ principal investigator, Alexander Neumeister, FDA investigators wrote that the research was fraught with violations that “jeopardize subject safety and welfare, and raise concerns about the validity and integrity of the data collected at your site.”

The trials, which were sponsored by pharmaceutical firm Pfizer, aimed to test the efficaciousness of a drug—a fatty acid amide hydrolase (FAAH) inhibitor. One study involved people suffering from post-traumatic stress disorder (PTSD), among other conditions. FAAH inhibitors are meant to simulate the effects of marijuana.

According to the New York Times, NYU suspended Neumeister after learning of the FDA’s conclusions, which included alleging that the researcher failed to follow up in a timely fashion with patients who had received the drug, and that he had forged a colleague’s name on study reports. After confirming the research misconduct, NYU’s psychiatric department chairman Charles Marmar placed Neumeister on leave; Neumeister later resigned.

“I honestly believed I had the best qualified and among the most ethical researchers on the faculty” running these studies, Marmar told the New York Times. Neumeister’s lawyer, Georges Lederman, told the paper that “NYU has taken the position that those violations were more egregious than we believe they actually were.”

According to Marmar, NYU has discarded all data gathered from one of the trials, which recruited 50 participants, and is checking on their health.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.